05:39 AM EST, 11/07/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) reported Q3 non-GAAP earnings late Wednesday of $6.61 per diluted share, up from $4.84 a year earlier.

Analysts polled by Capital IQ expected $5.50.

Revenue for the quarter ended Sept. 30 was $1.05 billion, up from $972.1 million a year earlier.

Analysts surveyed by Capital IQ expected $1.04 billion.

For 2024, the company said it now expects non-GAAP EPS to be in the range of $19.50 to $20.60 from the prior guidance of $19.20 to $20.30. Analysts polled by Capital IQ expect $19.84. Revenue for the year is still projected to be $4 billion to $4.10 billion. Analysts polled by Capital IQ expect $4.04 billion.